2-Hydroxybenzylamine (2-HOBA), a naturally occurring compound found in buckwheat, can protect cells and tissues from oxidative stress. In this study, 2-HOBA acetate was orally administered to male and female rats for 90 consecutive days at doses of 100, 500, and 1000 mg·kg BW −1 ·d −1 (n = 20 per sex/group). Subchronic administration of 2-HOBA was well tolerated at all dose levels. 2-HOBA-treated male rats were slightly heavier in the last weeks of the study, but this difference was very small (< 5%), did not show a dose-response relationship, and was not observed in female rats. Similarly, some statistically significant changes in serum biochemistry and hematology parameters were noted, but these were not considered to be of biological or toxicological significance. Sporadic differences in organ weights were observed between groups, but all were small (< 10%) and unlikely to indicate toxicity. The incidence of histopathological lesions was similar between treated and control groups across all organs. Based upon these findings, the no-observed-adverse-effect level was determined to be ≥ 1000 mg·kg BW
Introduction
2-Hydroxybenzylamine (2-HOBA) is a naturally occurring (Koyama et al., 1971 ) potent scavenger of γ-ketoaldehydes (Davies et al., 2002; Zagol-Ikapitte et al., 2010a) , which are highly reactive lipid aldehydes resulting from rearrangement of intermediates created during prostaglandin formation (Iyer et al., 1989; Murthi et al., 1993) or arachidonic acid oxidation (Brame et al., 1999; Morrow et al., 1990; Salomon and Miller, 1985) . γ-Ketoaldehydes react rapidly with proteins (Davies et al., 2002) and lipids (Bernoud-Hubac et al., 2009; Sullivan et al., 2010) to form adducts capable of altering protein function and inducing cellular stress and inflammation. By scavenging γ-ketoaldehydes, 2-HOBA can prevent the formation of these adducts and protect cells from the associated oxidative-stress induce damage.
The efficacy of 2-HOBA to protect against the cytotoxic effects of oxidative stress has been demonstrated in vitro (HepG2 cells) (Davies et al., 2006) . Further, 2-HOBA has shown beneficial effects in vivo across multiple organ systems and species. In C. elegans, 2-HOBA reduced oxidant injury biomarkers and increased lifespan (Nguyen et al., 2016) . In mice, 2-HOBA treatment prevented age-associated decrements in working memory in an Alzheimer's disease model (Davies et al., 2011) and reduced neuron loss and memory deficits in two epileptic injury models (Pearson et al., 2017) . 2-HOBA is also protective against hypertension. Administration of 2-HOBA has been shown to reduce angiotensin-II-induced hypertension (Kirabo et al., 2014) , prevent aortic stiffening and hypertension in mice with chronic vascular oxidative stress (Wu et al., 2016) , and ameliorate pulmonary arterial hypertension in BMPR2 mutant mice (Egnatchik et al., 2017) .
Thus far, in vitro safety studies (Fuller et al., 2018) and acute and short-term (28-day) in vivo rodent toxicity studies (Pitchford et al., 2018) of 2-HOBA have been completed. No potential safety concerns were identified in the in vitro studies. Similarly, no toxicologically significant effects were identified in the short-term rodent studies at doses up to 0.456% by weight in feed (mice) or 1000 mg·kg BW on the safety of 2-HOBA acetate administered over a longer duration remains necessary to support safe human consumption. Although 2-HOBA acetate has been administered to rodents daily for 8-10 months without noting any adverse effects (Davies et al., 2011) , this study was not designed to assess safety or toxicity. Thus, a longer formal toxicity study was warranted. The objective of the present study was to assess the effects of repeated oral administration of 2-HOBA acetate (administered daily for 90 consecutive days) in Wistar rats.
Materials and methods

Test article
2-HOBA (as 2-hydroxybenzylamine acetate, CAS 1206675-01-5) was provided by TSI (China) Co., Ltd. (Shanghai, China). Manufacturing Lot #16120312 was used for the present study. The lot purity was determined to be > 99%, as measured by high-performance liquid chromatography and nuclear magnetic resonance spectroscopy. The synthetic pathway and characterization methods are considered proprietary and are therefore not described in detail. 2-HOBA acetate was dissolved in a vehicle of 0.1% carboxymethylcellulose in water at concentrations of 0, 10, 50, or 100 mg/mL. Fresh solutions were prepared daily prior to animal dosing.
Animals and protocol
This study was conducted by Vedic Life Sciences, Pvt. Ltd. (Mumbai, India) in accordance with Organisation for Economic Co-operation and Development Good Laboratory Practice principles and following the guidelines described in Redbook (2000) IV.C.4.a Subchronic Toxicity Studies with Rodents (Office of Food Additive Safety, 2003). All experiments followed the National Institutes of Health guide for the care and use of laboratory animals (National Research Council, 2010) .
Male and female (n = 140/sex) 7-9 week old Wistar rats were used for this study. All rats were bred in-house at Vedic Life Sciences. Rats were individually housed in standard polycarbonate cages with corncob bedding and provided ad libitum access to standard laboratory rodent diet and reverse osmosis purified drinking water. The room temperature and relative humidity were maintained between 19.5 and 23.2°C and 45 and 58%, respectively, and a 12 h/12 h light/dark cycle was maintained. Individual housing was necessary to ensure accurate measurement of feed intake for each animal and is indicated in the outlined in the FDA Guidance (Office of Food Additive Safety, 2003). All rats were acclimatized to the test conditions for at least five days prior to dosing.
Rats were randomly allocated to groups based upon a ranking of the body weights of the animals in such a way that weight variation between groups was minimized. All animals randomized into the study ) underwent the same protocol for 90 days, but then recovered for 14 days without treatment before euthanasia and necropsy.
Observations
Animals were observed twice daily for morbidity and mortality and once daily for clinical signs, such as changes in skin, fur, eyes, or mucous membranes; secretions; changes in gait, posture, or handling response; clonic or tonic movements, and stereotypes or bizarre behavior. Ophthalmic examinations and a battery of functional observations were performed in the high dose (1000 mg·kg BW −1 ·d −1 ) and control groups at the end of treatment. All animals were weighed at randomization and weekly thereafter. Food consumption was also determined weekly.
Hematology, clinical chemistry, and urinalysis
Blood was collected for clinical chemistry, hematology, and coagulation factor analysis from 10 animals per group on days 15 and 45 and from all animals at necropsy. Animals were fasted overnight (14-16 h) before blood collection. Hematology parameters (white blood cell count, red blood cell count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet count, reticulocyte count, prothrombin time, partial thromboplastin time, neutrophils, lymphocytes, monocytes, eosinophils, and basophils) were measured using a hematology autoanalyzer (BC-2800, Mindray, Shenzhen, China). Clinical chemistry parameters (albumin, alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, calcium, chloride, cholesterol, creatinine, gamma glutamyl transferase, globulin, glucose, lactate dehydrogenase, phosphorous, potassium, sodium, sorbitol dehydrogenase, total bilirubin, total protein, triglycerides, blood urea nitrogen) were measured using an automated chemistry analyzer (LWC100plus, Landwind Medical, Shenzhen, China). Urine samples were collected from all animals at the end of the study using metabolic cages with urine collection tubes. Urine was evaluated for color and appearance (by observation) and specific gravity, pH, protein, glucose, bilirubin, blood, leukocytes, urobilinogen, and ketones (by autoanalyzer, Uro-dipcheck TM 300, ERBA Diagnostics, Mannheim, Germany).
Pathology and histopathology
Animals were euthanized on day 91 (primary groups) or day 105 (recovery groups) by CO 2 overdose. The adrenal glands, brain, heart, 171.9 ± 8.9 173.2 ± 7.9 174.8 ± 5.6 172.9 ± 6.9 173.9 ± 6.9 177.8 ± 6.0 175.9 ± 7.3 Week 6, g/d 173.6 ± 13.9 175.3 ± 5.6 177.1 ± 6.2 176.7 ± 6.1 164.6 ± 8.4* 177.8 ± 6.1 176.9 ± 6.5 Week 7, g/d 177.7 ± 10.5 178.9 ± 6.9 179.1 ± 6.4 181.2 ± 6.4 182.4 ± 6.1 181.9 ± 4.6 181.7 ± 5.7 Week 8, g/d 175.7 ± 8.0 179.3 ± 6.7 178.1 ± 7.9 181.1 ± 6.9 170.6 ± 13.9* 182.4 ± 6.2 181.4 ± 6.0 Week 9, g/d 180.9 ± 9.4 178. kidneys, liver, spleen, testes/ovaries, thyroid/parathyroid, and epididymis/uterus were collected, weighed, and fixed in 10% neutral formalin (with the exception of testes, which were fixed in modified Davidson's fluid). Additional tissues (aorta, bone, bone marrow, brain, eyes, cecum, colon, rectum, duodenum, ileum, jejunum, lungs, esophagus, trachea, pancreas, spinal cord, sternum, thymus, Harderian gland, lymph nodes, mammary glands, salivary glands, sciatic nerve, seminal vesicles, skeletal muscle, skin, prostate, and bladder) were also fixed for histology.
Statistical analysis
Statistical analyses were performed on body weights, body weight changes, food consumption, hematology, clinical chemistry, urinalysis, and organ weights. The low, mid, and high dose groups were compared with the vehicle control group, and the high dose recovery group was compared with the vehicle recovery group. Data sets were analyzed for homogeneity of variance using Levene's test followed by the Shapiro-Wilk test for normality. A p-value of < 0.001 was required for each test to reject the null hypothesis. If the Levene's test and the Shapiro-Wilk test were both not significant, a single-factor parametric analysis of variance (ANOVA) with group as the factor was applied using an α < 0.05 level of significance. If the parametric ANOVA was significant at p < 0.05, Dunnett's test was used to identify statistically significant differences between the vehicle control and each treated group (100, 500, and 1000 mg/kg BW d
) using an α of < 0.05. If either the Levene's test or the Shapiro-Wilk test were significant, then the Kruskal-Wallis non-parametric ANOVA with group as the factor was applied using an α < 0.05 level of significance. If the non-parametric Kruskal-Wallis ANOVA was significant at p < 0.05, Dunn's test was used to identify statistically significant differences between the vehicle control and each treated group (100, 500, and 1000 mg·kg BW
) using an α of < 0.05. The same decision tree was applied to determine any significant differences between the vehicle recovery and 1000 mg·kg BW −1 ·d −1 recovery groups. All data are expressed as mean ± standard deviation.
Results and discussion
Observations
All animals survived to scheduled necropsy. No clinical, ophthalmic, or behavioral abnormalities were observed. Body weight data are shown in Table 1 . Male rats in 2-HOBA treated groups were slightly (< 5%) heavier than control group rats during the last 2-3 weeks of the 90-day study; accordingly, 90-day weight gain was slightly (4-8%) 6 /μL 9.6 ± 1.8 9.5 ± 1.1 9.9 ± 0.9 8.6 ± 0.9* 9.3 ± 1.3 9.9 ± 0.9 9.7 ± 0.9 Neutrophil, % 13.7 ± 1.3 13.4 ± 1.2 13.6 ± 1.4 13.7 ± 1.3 13.3 ± 1.1 13.2 ± 1.3 13.3 ± 1.3 Lymphocyte, % 82.2 ± 1.3 82.6 ± 1.4 82.2 ± 1.7 82.0 ± 1.8 82.4 ± 1.5 82.5 ± 1.4 82.4 ± 1.7 Monocyte, % 2.7 ± 0.7 2.6 ± 0.7 2.7 ± 0.7 2.5 ± 0.6 2.7 ± 0.7 2.6 ± 0.7 2.7 ± 0.7 Eosinophil, % 1.5 ± 0.8 1.6 ± 0.6 1.6 ± 0.6 1.9 ± 0.6 1.8 ± 0.7 1.8 ± 0.7 1.7 ± 0.6 Basophil, % 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 PT, sec 11.0 ± 0.8 10.8 ± 1.2 11.1 ± 1.0 10.7 ± 1.1 11.0 ± 1.2 10.6 ± 1.0 11.2 ± 1.0* APTT, sec 16.3 ± 0.7 15.9 ± 0.6 16.3 ± 1.2 15.7 ± 0.8 15.7 ± 0.6 16.2 ± 0.9 15.6 ± 0.7* Females RBC, × 10 6 /μL 8.1 ± 0.5 7.8 ± 0.5 7.6 ± 0.4 7.5 ± 0.3 7.5 ± 0.3 7.5 ± 0.3 7.7 ± 0.4 HCT, % 44.6 ± 1.7 45. 6 /μL 9.9 ± 0.8 9.3 ± 1.2 8.6 ± 0.8 8.4 ± 0.9* 8.7 ± 0.7 8.4 ± 0.8 8.9 ± 0.7* Neutrophil, % 13.1 ± 1.3 13.9 ± 1.4 13.2 ± 1.3 13.6 ± 1.3 13.6 ± 1.4 13.4 ± 1.2 13.2 ± 1.4 Lymphocyte, % 83.1 ± 1.7 81.9 ± 1.5 82.5 ± 1.7 81.9 ± 1.3 82.3 ± 1.6 82.7 ± 1.5 82.8 ± 1.7 Monocyte, % 2.4 ± 0.8 2.8 ± 0.8 2.8 ± 0.8 2.9 ± 0.7 2.6 ± 0.7 2.6 ± 0.7 2.7 ± 0.7 Eosinophil, % 1.5 ± 0.5 1.5 ± 0.5 1.6 ± 0.6 1.7 ± 0.7 1.6 ± 0.7 1.5 ± 0.5 1.4 ± 0.5 Basophil, % 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 PT, sec 10.7 ± 1.3 10.7 ± 1.0 11.4 ± 1.0 11.3 ± 0.9 10.9 ± 1.0 10.9 ± 0.8 11.7 ± 1.3* APTT, sec 15.4 ± 0.7 15.4 ± 0.9 15.9 ± 0.8 15.4 ± 0.6 15.8 ± 0.9 16.0 ± 0.8 16. greater for 2-HOBA treated male rats. However, these observations were not apparent in the 1000 mg·kg BW −1 ·d −1 dose recovery group at any time point. Body weights were similar across groups in female rats. Body weight gain differed between groups in some weeks (data not shown), but there was no significant effect of 2-HOBA on 90-day weight gain. Some small, significant differences were observed in feed consumption between groups (Table 2 ), but these were inconsistently observed across time points and sexes. As all the observed significant differences between 2-HOBA treated and control rats were small, not dose-dependent, and not consistent across sexes and/or between primary and recovery groups, none were considered to be of biological or toxicological significance.
Hematology, clinical chemistry, and urinalysis
After 90 days of 2-HOBA acetate administration, some small (< 10%), sporadic differences in hematology were observed, as shown in Table 3 . None of the observed differences were dose-dependent, nor were any consistently observed between sexes. Considering this and the small magnitude of difference, none were considered to be biologically or toxicologically significant. There were no abnormal urinalysis findings in any of the experimental animals, nor were any differences observed between control and 2-HOBA treated animals (data not shown). Several significant differences were observed between groups in clinical chemistry parameters after 90 days of 2-HOBA acetate administration, as shown in Table 4 . The only clinical chemistry parameter that was significantly different in both male and female 2-HOBA treated rats was phosphorous, which was significantly higher in 2-HOBA treated rats of both sexes. Though phosphorous was also significantly higher in the male high dose recovery group, it was actually non-significantly lower in the female high dose recovery group when each sex was compared to the appropriate control group. The elevated serum phosphorous levels are unlikely to be due to kidney dysfunction, as the observed increases were modest and no other associated clinical or histopathological findings were indicative of kidney dysfunction or disease in 2-HOBA treated rats. While the observed mean values were elevated compared to the controls, others have reported higher mean clinical values than we observed in the present study (Caisey and King, 1980; Cray et al., 2009 ). Thus, the observed differences in serum phosphorous were not considered to be toxicologically significant. All 2-HOBA treated male rats had significantly higher serum cholesterol, triglycerides, alanine aminotransferase, and alkaline phosphatase levels compared to the vehicle control group rats. Interestingly, for cholesterol and triglycerides, while the 2-HOBA treated groups all differed significantly from the vehicle control group, the observed values were similar to those observed for the water control group and were within the normal range for Wistar rats (He et al., 2017) , raising the possibility that the vehicle control group may have had incidentally lower values for these parameters. Further, none of these findings were dose-dependent or observed in the high dose recovery group. Total protein was significantly lower in the male high dose and high dose recovery groups compared to their respective control groups, but the magnitude of these differences was less than 10%, and overall the serum protein was greater in this group of rats than for some reference intervals found in the literature for male rats (Boehm et al., 2007) . In female rats, blood urea nitrogen was significantly lower in all 2-HOBA treatment groups, but higher in the high dose recovery group, suggesting no consistent effect of 2-HOBA on blood urea nitrogen. All female 2-HOBA treatment groups also had significantly higher potassium and lower chloride levels compared to the vehicle control group, but these differences were not dose-dependent or observed in the high dose recovery group. The potassium values from low and high dose animals were only slightly above ranges found in the literature and the mid dose was within the ranges found for potassium values (Liberati et al., 2004) . Additionally, the observed serum chloride values were also within the range found in the literature for female Wistar rats (Liberati et al., 2004) . Other significant differences were inconsistently observed within treatment and/or recovery groups. In summary, as most of these differences were small, not dose-dependent, and/or not observed in both sexes, therefore none of the differences were considered to be of biological or toxicological significance.
Blood samples collected from a subset of animals (10 per group) on days 15 and 45 were also analyzed for hematology and clinical chemistry parameters. Similar to the findings at the study conclusion, though several statistically significant differences were observed between control and treatment groups, none were consistent between treatment and recovery groups or between sexes. Further, none of the differences were consistently observed across timepoints in any group. In the interest of space, these data are not shown.
Pathology and histopathology
No gross pathologies were observed upon external or internal examination. Organ weights (gross and relative to body mass) are shown in Tables 5 and 6 . Few differences in organ weights were observed between groups, and all significantly different values varied less than 10% different from the appropriate vehicle control group, suggesting no toxicological effects of 2-HOBA on organ weight.
Histopathological examination revealed several findings, but all were observed at similar frequencies across 2-HOBA treated and control groups. Mild to moderate thickening of the wall of the alveolar region of the lungs, alveolar inflammation, and/or peribronchiolar lymphoid hyperplasia and inflammation were observed across groups (17/40 control, 14/40 high dose, 9/40 control recovery, and 9/40 high dose recovery). Liver lesions (sinusoidal hemorrhage, foci of necrosis, inflammation, and/or mononuclear cell infiltration) were also observed at similar frequency in all groups (6/40 control, 6/40 high dose, 4/40 recovery control, and 5/40 recovery high dose). Mild inflammation, congestion, and/or hemorrhage were noted in kidney from control (6/ 40), high dose (7/40), control recovery (8/40), and recovery high dose (7/40) groups. Intestinal lesions (submucosal lymphoid hyperplasia or mucosal inflammation of the ileum or colon) were observed in control (9/40), high dose (5/40), recovery control (8/40), and recovery high dose (6/40) rats. Mild foci of inflammatory cell infiltration were noted in the myocardium of one animal in the control group (1/40) and one animal in the recovery control groups (1/40), but neither the high dose or high dose recovery groups had any heart changes. Mild foci of necrosis were noted in the brain of one animal from the high dose group (1/40) and three animals from the recovery control group (3/40). Lymphoid follicular depletion was detected in the spleen of one control animal and congestion was noted in one control group and one recovery control group animal. Ovarian hemorrhage was noted in one high dose group female rat (1/20) and one high dose recovery group rat (1/20), and submucosal glandular degeneration was noted in the uterus of one high dose group female rat (1/20). Though several histopathological changes were observed in the high dose and high dose recovery groups, none of the lesions were specific to 2-HOBA-treated animals and were observed at similar frequencies in treated and control animals. Thus, all histopathological observations were considered to be spontaneous in nature and not related to 2-HOBA administration.
Conclusions
Although 2-HOBA acetate has been administered to rodents for extended time periods (up to 10 months) in mechanistic studies (Davies et al., 2011; Pearson et al., 2017; Kirabo et al., 2014; Wu et al., 2016; Egnatchik et al., 2017; Zagol-Ikapitte et al., 2010b) , the present study is the longest duration toxicity study of 2-HOBA acetate to date. There were no biologically or toxicologically significant findings observed in male or female rats at doses up to 1000 mg·kg BW
acetate (the highest dose tested). The human equivalent doses of 2-HOBA to those tested in this study range from 13.5 to 135 mg/kg, as calculated based on the FDA-recommended body surface area calculations (Food and Drug Administration, 2005) . Thus, the highest tested dose translates to a dose of ∼10 g per day for a 75-kg man, which far exceeds the intended dose levels for humans. The lack of toxicity in this study provides further support the safety of orally administered 2-HOBA acetate and the continued development of 2-HOBA acetate as a functional food or dietary supplement. Future toxicity studies should investigate the effects of 2-HOBA acetate administration in a non-rodent species to improve the generalizability of these safety findings across species. ) for 90 days, then recovered for 14 days before euthanasia.
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